肝细胞激活转录因子 3 通过调节高密度脂蛋白和胆汁酸代谢来保护动脉粥样硬化。
Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism.
机构信息
Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.
Zhongshan Institute for Drug Discovery, the Institutes of Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan, China.
出版信息
Nat Metab. 2021 Jan;3(1):59-74. doi: 10.1038/s42255-020-00331-1. Epub 2021 Jan 18.
Activating transcription factor (ATF)3 is known to have an anti-inflammatory function, yet the role of hepatic ATF3 in lipoprotein metabolism or atherosclerosis remains unknown. Here we show that overexpression of human ATF3 in hepatocytes reduces the development of atherosclerosis in Western-diet-fed Ldlr or Apoe mice, whereas hepatocyte-specific ablation of Atf3 has the opposite effect. We further show that hepatic ATF3 expression is inhibited by hydrocortisone. Mechanistically, hepatocyte ATF3 enhances high-density lipoprotein (HDL) uptake, inhibits intestinal fat and cholesterol absorption and promotes macrophage reverse cholesterol transport by inducing scavenger receptor group B type 1 (SR-BI) and repressing cholesterol 12α-hydroxylase (CYP8B1) in the liver through its interaction with p53 and hepatocyte nuclear factor 4α, respectively. Our data demonstrate that hepatocyte ATF3 is a key regulator of HDL and bile acid metabolism and atherosclerosis.
激活转录因子 (ATF)3 具有抗炎功能,然而肝 ATF3 在脂蛋白代谢或动脉粥样硬化中的作用尚不清楚。在这里,我们表明在肝细胞中过表达人 ATF3 可减少西方饮食喂养的 Ldlr 或 Apoe 小鼠动脉粥样硬化的发展,而肝细胞特异性敲除 Atf3 则有相反的效果。我们进一步表明,肝 ATF3 的表达受氢化可的松抑制。在机制上,肝细胞 ATF3 通过诱导清道夫受体 B 型 1(SR-BI)和通过其与 p53 和肝细胞核因子 4α的相互作用分别抑制胆固醇 12α-羟化酶(CYP8B1),增强了高密度脂蛋白(HDL)的摄取,抑制了肠道脂肪和胆固醇的吸收,并促进了巨噬细胞胆固醇逆向转运。我们的数据表明,肝细胞 ATF3 是 HDL 和胆汁酸代谢和动脉粥样硬化的关键调节因子。
相似文献
引用本文的文献
Microorganisms. 2025-5-27
Front Immunol. 2024
Commun Biol. 2024-10-10
本文引用的文献
Arterioscler Thromb Vasc Biol. 2019-7-11
J Clin Endocrinol Metab. 2019-12-1
Nat Rev Endocrinol. 2019-6-27
Hepatol Commun. 2019-3-25
J Int Med Res. 2019-4
Eur J Clin Invest. 2017-7
Medicine (Baltimore). 2017-5
Am J Physiol Endocrinol Metab. 2017-8-1